Home › Uterine Cancer
Uterine Cancer clinical trials recruiting in the U.S.
29 studies for Uterine Cancer are recruiting participants at sites across the United States.
Uterine cancer is a cancer that forms in tissues of the uterus. It is more likely to happen after menopause. There are things you can do that may help lower your risk.
Cities with the most studies
- Houston, TX8 studies
- New York City, NY7 studies
- Boston, MA7 studies
- Columbus, OH6 studies
- Austin, TX6 studies
- Philadelphia, PA6 studies
- Miami, FL5 studies
- Nashville, TN5 studies
- Orlando, FL4 studies
- Pittsburgh, PA4 studies
- West Palm Beach, FL4 studies
- Providence, RI4 studies
- Dallas, TX4 studies
- Portland, OR4 studies
- Arlington, VA4 studies
- Baltimore, MD4 studies
- Birmingham, AL3 studies
- Chicago, IL3 studies
- St. Louis, MO3 studies
- San Antonio, TX3 studies
- Indianapolis, IN3 studies
- Camden, NJ3 studies
- Fort Worth, TX3 studies
- St. Petersburg, FL3 studies
- Minneapolis, MN3 studies
- Cape Coral, FL3 studies
- Cleveland, OH3 studies
- Baldwin Park, CA3 studies
- Harrisburg, PA3 studies
- Miami Beach, FL3 studies
- Oklahoma City, OK3 studies
- San Diego, CA3 studies
- Eugene, OR3 studies
- San Francisco, CA3 studies
By state
- Alabama3 studies
- Arizona3 studies
- California10 studies
- Florida7 studies
- Georgia3 studies
- Illinois4 studies
- Indiana3 studies
- Maryland5 studies
- Massachusetts7 studies
- Michigan4 studies
- Minnesota5 studies
- Missouri4 studies
- New Jersey7 studies
- New York9 studies
- North Carolina4 studies
- Ohio7 studies
- Oklahoma4 studies
- Oregon5 studies
- Pennsylvania8 studies
- Rhode Island4 studies
- Tennessee5 studies
- Texas11 studies
- Virginia5 studies
- Washington3 studies
Recently updated studies
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
RecruitingPhase 1
Ages 18 and older · Women · Updated Nov 13, 2026 · NCT06964009Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
RecruitingPhase 4
Ages 18 and older · Women · Updated Nov 5, 2026 · NCT06952660Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07542704Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
Recruiting
Ages 18 and older · Women · Updated Oct 15, 2026 · NCT05990426DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 13, 2026 · NCT06989112Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
RecruitingPhase 1
Ages 18 and older · Women · Updated Oct 13, 2026 · NCT06795009Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
RecruitingObservational study
Ages 18 and older · Women · Updated Oct 7, 2026 · NCT05049538Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT04038619PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT05758688Sentinel Node Biopsy in Endometrial Cancer
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 15, 2026 · NCT04073706Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
RecruitingPhase 2
Ages 18 and older · Women · Updated Aug 27, 2026 · NCT06492070PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT04329494Investigations of Reproductive Cancers in Women
RecruitingObservational study
Ages 45 to 100 · Women · Updated Aug 17, 2026 · NCT06527157Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Aug 13, 2026 · NCT06040970Hypofractionated Radiochemotherapy
RecruitingPhase 2
Ages 18 to 120 · Women · Updated Jul 30, 2026 · NCT06331468Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 29, 2026 · NCT07044336A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Initial Testing of a Behavioral Intervention About Genetic Services for Families at Risk of Lynch Syndrome
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Jul 21, 2026 · NCT07106359[18F]FES PET/.CT in Uterine Cancer
RecruitingPhase 2
Ages 18 and older · Women · Updated Jun 5, 2026 · NCT05916196Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Apr 15, 2026 · NCT05559879Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking
RecruitingObservational study
Ages 18 to 90 · Women · Updated Mar 6, 2026 · NCT05977621Azenosertib in Uterine Serous Carcinoma: Biomarker Study
RecruitingPhase 2
Ages 18 and older · Women · Updated Mar 2, 2026 · NCT06369155With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
Recruiting
Ages 21 and older · Women · Updated Feb 25, 2026 · NCT05721976Sample Collection for Ongoing Research and Product Evaluation Study
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 15, 2026 · NCT07318051From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.